Patients receiving post-transplant cyclophosphamide to prevent graft-versus-host disease have lower risk for bronchiolitis obliterans syndrome.

After over a decade with HIV, a Norwegian man received a surprise through a stem cell donation from his sibling. The gifted ...

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL ...

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

Global CAR T-cell Therapy Market OverviewThe global CAR T-cell therapy market is poised for exceptional growth, with an ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an ...

The honorees are scheduled to deliver lectures during this year’s meeting in San Diego, CA, which runs from April 17-22.

Hospitals can feel overwhelming when you’re going through cancer treatment, which is why many now bring in therapy animals to ...

Mesoblast offers asymmetric risk-reward with Ryoncil's rapid pediatric SR-aGvHD launch and multiple late-stage pipeline catalysts. Learn why MESO stock is a hold.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented ...

Allogene announced the futility analysis, which was triggered by the protocol-defined data cutoff of the 24 th patient completing Day 45 minimal residual disease (“MRD”) assessment, showed that 58.3% ...

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children ...